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Abstract
Background: Skin cancer, including basal cell carcinoma (BCC), has become a major health care problem. The limitations of
a punch biopsy (at present the gold standard) as diagnostic method together with the increasing incidence of skin cancer point
out the need for more accurate, cost-effective, and patient friendly diagnostic tools. In vivo reflectance confocal microscopy
(RCM) is a noninvasive imaging technique that has great potential for skin cancer diagnosis.
Objective: To investigate whether in vivo RCM can correctly identify the subtype of BCC and to determine the cost-effectiveness
of RCM compared with punch biopsy (usual care). Study design: Randomized controlled multicenter trial.
Methods: On the basis of 80% power and an alpha of 0.05, 329 patients with lesions clinically suspicious for BCC will be
included in this study. Patients will be randomized for RCM or for a punch biopsy (usual care). When a BCC is diagnosed, surgical
excision will follow and a follow-up visit will be planned 3 months later. Several questionnaires will be filled in (EQ-5D, EQ-5D
VAS, iMTA PCQ, and TSQM-9). We will perform statistical analysis, cost-effectiveness, and patient outcome analysis after data
collection.
Results: This research started in January 2016 and is ethically approved. We expect to finish this study at the end of 2018.
Conclusions: In this study, we will investigate whether RCM is at least as good in identifying BCC subtypes as conventional
pathological investigation of skin biopsies. Anticipating that RCM is found to be a cost-effective alternative, it saves on direct
medical consumption like labor of the pathologist and other medical personnel as well as materials related to treatment failure
with at least equal effectiveness.
Trial Registration: Clinicaltrials.gov NCT02623101; https://clinicaltrials.gov/ct2/show/NCT02623101 (Archived by WebCite
at http://www.webcitation.org/6id54WQa2)
(JMIR Res Protoc 2016;5(2):e114)   doi:10.2196/resprot.5757
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Introduction
Skin Cancer
Skin cancer is a common type of cancer and its incidence is
increasing rapidly in Western countries [1-3]. This cancer
comprises two types: melanoma (MM) and nonmelanoma skin
cancer (NMSC). NMSC is further divided into basal cell
carcinoma (BCC), squamous cell carcinoma (SCC), and its
precursors actinic keratosis (AK) and Bowen disease. In the
Netherlands, the registry of NMSC is poor. However, based on
recent literature and guidelines, it is estimated that the incidence
of malignant skin tumors and the premalignant AK is around
235,000 in 2015. This will have a major impact on our health
care system. Moreover, it is predicted that numbers will rise at
the rate of 4.5-8% per year, depending on the type of skin
cancer. Currently, in case of suspicion of NMSC, the
pathological examination of a punch biopsy is the gold standard,
according to the Dutch guidelines. In case of clinical suspicion
of AK, the diagnosis is made à vue, without pathological
confirmation. Already in 2003 in the United States, skin cancer
was found to be among the most costly of all cancers to treat.
Therefore, it is evident that skin cancer places an enormous
burden on health care systems with increasing costs [4]. In case
of suspicion of skin cancer, it is important to diagnose and treat
it in an early phase, preferably in a patient friendly manner. As
BCC is the most common skin cancer (about 75% of all skin
cancers), this study will focus on studying this skin cancer type.
Clinically, BCC can vary in appearance but is often
characterized by small, translucent, or pearly papules, with
telangiectasias [5]. In the past, the diagnosis was mainly made
clinically. However, noninvasive therapies have become
available; therefore, determination of the BCC subtype has
become more important. For this reason, pathological analysis
of a punch biopsy is currently the gold standard to confirm the
clinical diagnosis and determine the subtype of BCC. The
following subtypes of BCC can be distinguished: superficial
(sBCC), nodular (nBCC), aggressive BCC (micronodular
(mnBCC), and infiltrative (iBCC)) [6]. It is experienced that
there is a sample error in 29% of the cases with the conventional
diagnostic procedure, resulting in an incorrect subtype diagnosis
[7]. For this reason and because of the increasing incidence of
skin cancer, more accurate, cost-efficient, and patient friendly
diagnostic tools are desirable.
Reflectance Confocal Microscopy
Reflectance confocal microscopy (RCM) is a noninvasive
imaging technique. It provides real-time images of cell and
tissue structures and in vivo dynamics, without the need for ex
vivo tissue samples. RCM visualizes human skin up to a depth
of around 250 μm [8-12]. Refractive index differences between
cells and surrounding tissue provide the contrast. The contrast
of RCM imaging of the skin is mainly provided by melanin and
keratin [10]. Most, but not all, tumors can be visualized. For
thicker tumors, RCM may help to find the optimal localization
to perform a punch biopsy, as superficial features in these tumors
may help to spot these lesions [13]. Moreover, RCM can image
the whole tumor. RCM features for NMSC have been described
that showed a high correlation with conventional pathological
features [13-15]. These features allow diagnosing AK, SCC,
and BCC [13-15]. For both the BCC subtypes, nodular and
micronodular BCC, the following RCM characteristics are
described: tumor nests with peripheral palisading, branch-like
structures, fibrotic septa, and increase of vascular diameter. The
size and shape of the tumor nests allows further distinction
between these BCCs. Solar elastosis and tumor nests connected
with the basal cell layer characterize superficial BCC [14].
iBCCs are more challenging to visualize due to their histological
complex appearance and deeper location [16].
Only few studies report data about diagnostic accuracy of RCM
for primary BCC diagnosis [14,16-19]. These studies show a
high sensitivity and specificity for RCM as diagnostic tool for
BCC. Although these show the potential of RCM in BCC
diagnosis, prospective large-scale studies are lacking. In addition
to BCC diagnosis by RCM in general, no diagnostic accuracy
data were reported on determination of BCC subtype by RCM.
Such studies are required for implementation of RCM in the
routine patient care and incorporation into the health insurance
system. Implementation of RCM in the routine patient care
settings has the advantage of making a diagnosis at the first
consultation and therefore, the patient can be treated at short
term. A second consultation for explaining the diagnosis and
performing the treatment might be unnecessary. Therefore, time
saved by using the RCM can be used for other new patients.
Objectives
The primary objective of this study is to investigate whether in
vivo RCM can identify the subtype of BCC at least as correctly
as a skin punch biopsy. We are hypothesizing that RCM imaging
allows correct identification of the BCC subtype (nBCC,
mnBCC, sBCC, iBCC, and mixed type BCC), and true and false
positive results are equal or better as compared with
conventional pathological investigation of skin biopsies (gold
standard). It is postulated that RCM is more cost-effective and
patient friendly compared with the current procedure. Therefore,
the quality of life (Qol), costs, and quality adjusted life years
(QALYs) will be evaluated as the secondary outcome measures.
Overall, with the implementation of RCM in dermatology skin
cancer care, it is aimed to contribute to cost-effective,
noninvasive, patient friendly diagnostics.
Methods
Recruitment, Inclusion, and Study Design
Patients with lesions clinically suspicious (diagnosis à vue) for
BCC, eligible for RCM, visiting the dermatological departments
of the Radboud University Medical Center, Nijmegen, the
Canisius Wilhelmina Hospital, Nijmegen, and the Rijnstate
Hospital Arnhem-Velp, in The Netherlands will be asked to
join this study.
In order to be eligible for participation in this study, a subject
must meet all of the following criteria:
• Patients must be 18 years and above.
• Patients must be able to adhere to all requirements of the
study.
• Patients must be willing to give written informed consent.
• There must be clinical diagnosis/clinical suspicion of basal
cell carcinoma.
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A potential subject who meets any of the following criteria will
be excluded from participation in this study:
• A patient participating in other investigational research
currently or in the previous 28 days before the study
• Patient having a medical condition which excludes
participating the research, according to the investigator
• Incapacitated subjects
• Subjects with lesion(s) on parts of the body which do not
allow adequate imaging of the tumor with RCM
When a patient meets these criteria and gives informed consent,
he or she is assigned to a randomization arm according to a
computer-generated block randomization (Castor) (Figure 1).
Figure 1. Scheme of randomization. Two randomization arms are designed. After inclusion, a patient with a clinical diagnosis of BCC (diagnosis à
vue) will be randomized over the two arms. One arm contains the standard procedure of a biopsypunch biopsy, the other arm contains the diagnostic
tool to be investigated: RCM. A punch biopsy will also be obtained when there is no suspicion of a BCC using RCM.
Power Calculation
The primary outcome in this study is the percentage of correctly
identified subtype of confirmed BCC after excision (gold
standard in this study). We assume that this is 71% when a
punch biopsy is used and 85% when RCM is used (based on an
ongoing study). In this case, 148 patients are needed per group
to obtain a power of 80% (Fisher’s-exact, two-sided,
alpha=0.05). We expect that 10% of the patients with a clinically
suspected BCC will not have histopathologically confirmed
BCC. Therefore, we will include approximately 329 patients
with a clinical suspicion of BCC. In this multicenter randomized
controlled trial (RCT), it is also possible to obtain empirical
estimates of the (cost-) effectiveness in daily clinical practice,
beyond the diagnostic value. The expected benefit of the
experimental diagnostic tool is anticipated at €92 per patient.
On the basis of a conservative choice of the SD of €100 and the
CI of 95%, 146 patients per group are required. Counting a 10%
possible dropouts, around 322 patients need to be included.
To answer both questions, in total 329 patients suspected with
a clinical suspected BCC will be included in this study.
Outcome Measures
The primary outcome measure is defined as correct subtyping
of the BCC after excision. The histopathological diagnosis of
the excision specimen will be compared with either the diagnosis
made by RCM or a punch biopsy. Secondary outcome measures
are Qol, Cost, and QALYs.
Procedure
Patients will be assigned to either the RCM or the punch biopsy
study arm (Figure 1). When a BCC is diagnosed using RCM or
the gold standard (punch biopsy), surgical excision will follow
according to standard care-time schedule at the center where
the BCC is diagnosed with margins according to the guidelines
(3 mm for sBCC and nBCC, 5 mm for aggressive BCC). In case
of a BCC, a follow-up visit will be planned 3 months after
surgery. If the diagnosis reveals the absence of a BCC, the
patients will again be followed-up after 3 months. During visit
1 (diagnostic procedure) several questionnaires will be filled in
(EQ-5D, EQ-5d VAS, iMTA PCQ, and TSQM-9). At the
follow-up visit after treatment, the questions about satisfaction
of the diagnostic procedure will be asked again. In order to
establish the added monetary value of RCM, a contingent
valuation method (CVM) was used. Patients that belong to the
RCM arm and also had a punch biopsy, in which both diagnosis
had the absence of a BCC, were interviewed according to the
CVM.
RCM will be performed with the commercially available
Vivascope 1500 (Caliber imaging & diagnostics, Rochester,
NY, USA) according to a standardized protocol. Vivablocks of
4 × 4 mm will be made at the level of the stratum corneum,
stratum spinosum, dermal epidermal junction, and dermis in
order to find RCM features for BCC and the subtype. Vivastacks
will be made in the areas of interest. Movies will be made to
document vascularization. When indicated, the Vivascope 3000
handheld device will be used. The RCM user is working for 4
years with the device. If a punch biopsy needs to be obtained
according to the randomization scheme, this will occur after
local anesthesia (1% xylocaine/adrenaline) and the punch biopsy
will have a diameter of 3 mm. The punch biopsy will be taken
from the most clinically suspected area of the lesion.
Analysis
After data collection, analyses will be performed. The
Fisher’s-exacts test will be used to test the differences in the
primary outcome between the two study arms (biopsy, RCM)
for statistical significance. Multivariable logistic regression will
be used to study possible differences between the subtypes and
the effect of possible other variables. This will be done in order
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to evaluate variables or sets of variables for its discriminative
character that can be used to make protocols and guidelines for
future Dutch RCM users.
Cost-Effectiveness Analysis
The cost analysis comprises two main parts. First, on patient
level, volumes of care will be measured prospectively over the
time path of the clinical trial using the iMCQ (a generic
instrument for measuring medical costs [20]) complemented
with procedure specific cost information like cost of RCM
equipment and patient out-of-pocket expenses, such as
over-the-counter drugs (for example pain related). Relevant,
(missing) entries will be verified or completed by data from the
medical records or inpatient treatment facility’s administration
system. Second, per modality (RCM or usual care) standard
cost prices will be determined using the Dutch guideline [21]
or else real/full cost prices via activity-based costing.
Productivity losses will be estimated using a patient-based
questionnaire [22]. The friction-cost method will be applied
following the Dutch guidelines [21].
Patient Outcome Analysis
The effect analysis adheres to the design of a
superiority/equivalent RCT and measures diagnostic
performance and Qol at baseline, and at fixed points along the
follow-up of the RCT. To measure the quality of the health
status of the patients, a validated so-called health-related quality
of life (HRQoL) instrument will be used, the EuroQol-5D-3L
(EQ-5D) [23]. This HRQoL instrument will be completed by
the patients and is available in a validated Dutch translation
[24]. The EQ-5D is a generic HRQoL instrument comprising
five domains: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. The EQ-5D index is
obtained by applying predetermined weights to the five domains.
This index gives a societal-based global quantification of the
patient’s health status on a scale ranging from 0 (death) to 1
(perfect health). Patients will also be asked to rate their overall
HRQoL on a visual analogue scale (EQ-5D VAS) consisting
of a line ranging from 0 (worst imaginable health status) to 100
(best imaginable). The patient outcome analysis will be
complemented with a CVM questionnaire and measures of
satisfaction and pain related to diagnosing subtype BCC.
Results
This investigator initiated multicenter RCT is conducted
according to the principles of the Declaration of Helsinki (2013)
and in accordance with the medical Research Involving Human
Subjects Act (WMO). The study is funded by ZonMw, a Dutch
organization that finances health science, and thereby stimulates
the use of obtained knowledge to improve health care. The
medical ethics committee (NL 54549.091.15) approved the
study protocol in December 2015. The study will start in January
2016, and is expected to finish until the end of 2018. This trail
had also been registered at ClinicalTrails.gov (nr:
NCT02623101).
Discussion
Considering the increasing skin cancer problem, including BCC,
and the disadvantages of the current diagnostic gold standard,
histopathological diagnosis of a punch biopsy, indicates the
need for cost- and time-efficient diagnostic tools with high
accuracy for diagnosing skin cancers. These tools should be
able to distinguish between skin cancer types and should be
able to determine the correct BCC subtype, as different subtypes
of BCCs are treated differently. Biopsies often result in sampling
errors, as only a small part of the tumor is investigated resulting
in potentially inappropriate chosen therapies. As a sample error
may lead to treatment failures or recurrences, other subsequent
treatments are needed. This will eventually lead to increasing
costs. In addition, the conventional method is unfriendly for
patients, as it is invasive, painful, and might result in scarring.
Furthermore, the diagnosis cannot be made instantly.
To contribute to implementation of RCM as noninvasive skin
cancer diagnostic tool, this study will investigate whether RCM
is at least as good in identifying BCC subtypes as conventional
histopathological investigation of skin biopsies. Hypothesizing
that RCM is a cost-effective alternative to the present care, it
saves on direct medical consumption like labor of the pathologist
and other medical personnel as well as materials related to
treatment failure with at least equal effectiveness.
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